Dr. Borad received his MD from Rutgers New Jersey Medical School, completed internal medicine training at Cedars-Sinai, medical oncology training at Tulane University, and was a Genomics Medicine and Drug Development Scholar at TGen under the tutelage of Dr. Daniel Von Hoff. His team was the first to demonstrate anti-tumor activity in FGFR2-fusion cholangiocarcinomas using small molecule FGFR2 inhibitors and to introduce an oncolytic Rhabdovirus into human clinical studies. His work is supported by grants from the US NIH, NCI, DOD and FDA. He is currently a Professor of Medicine, Program Leader for the Gene and Virus Therapy Program, and Director of the Precision Cancer Therapeutics Program at Mayo Clinic.
